Developing Cyclodextrin as a small molecule compound for Parkinson’s disease treatment.

SCHEME: PATHFINDER

CALL: 2018

DOMAIN: BM - Life Sciences, Biology and Medicine

FIRST NAME: Jens

LAST NAME: Schwamborn

INDUSTRY PARTNERSHIP / PPP: No

INDUSTRY / PPP PARTNER:

HOST INSTITUTION: University of Luxembourg

KEYWORDS: Parkinson's disease, drug development, autophagy, cyclodextrin

START: 2019-01-01

END: 2020-12-31

WEBSITE: https://www.uni.lu

Submitted Abstract

Parkinson’s disease (PD) is an age associated progressive neurodegenerative disorder. So far no therapeutic approach for the inhibition of the disease progression has been described. We recently described a small molecule compound with the potential to modify the progression of PD and thereby to act as a therapeutic molecule. Here we want to further develop this molecule and explore the potential acceptance of the market for this approach.Within the PATHFINDER project, we mainly aim at evaluating the interest of potential future partners (e.g. pharma companies) and get an overview of their requirements. Additionally, together with the Lead Discovery Centre we will get a first overview whether medicinal chemistry modifications of our initial hit compound are possible and protectable. After a successful PATHFINDER project, we aim at conducting a proof-of-concept study to test novel modifications of the initial hit compound in advanced in vitro disease models (including brain organoids). This shall be done as part of a new initiative between LCSB and LIH to jointly conduct drug development campaigns.

This site uses cookies. By continuing to use this site, you agree to the use of cookies for analytics purposes. Find out more in our Privacy Statement